{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:36:05Z","timestamp":1787016965510,"version":"build-2736575974"},"reference-count":16,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,8,20]]},"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>\n                    Patients with AIDS have increased risk of developing lymphomas, such as anaplastic large cell lymphoma (ALCL), which generally carry a poor prognosis. The\n                    <jats:italic>DUSP-IRF4<\/jats:italic>\n                    genetic rearrangement in ALCL confers a favourable prognosis in HIV-negative patients; it is unknown how this interacts clinically with HIV\/AIDS. A man aged 53 years presented with subcutaneous nodules on the scalp and axillae, and diffuse lymphadenopathy. Biopsy of subcutaneous nodule and lymph node showed large atypical anaplastic lymphocytes which were CD30+ and anaplastic lymphoma kinase-negative, consistent with primary systemic ALCL. In addition, he was found to be HIV-positive and diagnosed with AIDS. Genetic testing of the tissue revealed a\n                    <jats:italic>DUSP22-IRF4<\/jats:italic>\n                    rearrangement. Complete remission was achieved with HyperCVAD and subsequent brentuximab vedotin monotherapy. We report a case of AIDS-associated primary systemic ALCL with a\n                    <jats:italic>DUSP22-IRF4<\/jats:italic>\n                    rearrangement. AIDS-associated ALCL is an aggressive lymphoma, with a poor prognosis. However, the presence of the genetic rearrangement, previously unseen in this disease, drastically altered the disease course. This case highlights the value of genetic testing and identifies\n                    <jats:italic>DUSP22-IRF4-<\/jats:italic>\n                    associated ALCL in the setting of HIV-associated lymphoproliferative disorders.\n                  <\/jats:p>","DOI":"10.1136\/bcr-2019-230641","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T18:52:20Z","timestamp":1569869540000},"page":"e230641","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["<i>DUSP22-IRF4<\/i>\n                    rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02298257","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01771107","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6487-5912","authenticated-orcid":false,"given":"Mike","family":"Wang","sequence":"first","affiliation":[{"name":"Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Kibbi","sequence":"additional","affiliation":[{"name":"Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Ring","sequence":"additional","affiliation":[{"name":"Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Siddon","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Pathology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Foss","sequence":"additional","affiliation":[{"name":"Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA"},{"name":"Hematology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Totonchy","sequence":"additional","affiliation":[{"name":"Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"2025082800323986000_12.9.e230641.1","first-page":"34","article-title":"Pantanowitz L: Peripheral T-cell lymphomas in HIV-infected individuals: a comprehensive review","volume":"14","author":"Castillo","year":"2009","journal-title":"J HIV Ther"},{"key":"2025082800323986000_12.9.e230641.2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903572201"},{"key":"2025082800323986000_12.9.e230641.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"2025082800323986000_12.9.e230641.4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.320"},{"key":"2025082800323986000_12.9.e230641.5","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.225"},{"key":"2025082800323986000_12.9.e230641.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571091"},{"key":"2025082800323986000_12.9.e230641.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-755496"},{"key":"2025082800323986000_12.9.e230641.8","doi-asserted-by":"crossref","first-page":"68734","DOI":"10.18632\/oncotarget.11930","article-title":"Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes","volume":"7","author":"M\u00e9lard","year":"2016","journal-title":"Oncotarget"},{"key":"2025082800323986000_12.9.e230641.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-838524"},{"key":"2025082800323986000_12.9.e230641.10","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/his.13163","article-title":"Indolent ALK-negative anaplastic large-cell lymphoma, DUSP22 rearranged, with an unusual immunophenotype in a human immunodeficiency virus patient","volume":"70","author":"Chapman","year":"2017","journal-title":"Histopathology"},{"key":"2025082800323986000_12.9.e230641.11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21947"},{"key":"2025082800323986000_12.9.e230641.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"2025082800323986000_12.9.e230641.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"2025082800323986000_12.9.e230641.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780049"},{"key":"2025082800323986000_12.9.e230641.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-821009"},{"key":"2025082800323986000_12.9.e230641.16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QAD.0000000000001729","article-title":"Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma","volume":"32","author":"Rubinstein","year":"2018","journal-title":"AIDS"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-230641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:32:49Z","timestamp":1756366369000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-230641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,30]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1136\/bcr-2019-230641"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-230641","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}